Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progestogen for preventing miscarriage.

David M Haas1, Patrick S Ramsey

  • 1Indiana University School of Medicine, Wishard Memorial Hospital, 1001 West 10th Street, F-5, Indianapolis, IN 46202, USA.

The Cochrane Database of Systematic Reviews
|April 22, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of maternal obesity on ultrasonographic characterization of placenta accreta spectrum.

American journal of obstetrics & gynecology MFM·2026
Same author

Large-scale proteomics and timing of hypertensive disorders of pregnancy.

medRxiv : the preprint server for health sciences·2026
Same author

Endothelial Susceptibility-Related Genetic Variants and Hypertensive Disorders of Pregnancy-Brief Report.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Harmonizing Maternal and Infant Biospecimen Collection and Processing for Research.

Biopreservation and biobanking·2026
Same author

Fetal brain volumes and brain gyrification index associated with opioid exposure.

Brain communications·2026
Same author

Association between a Periconception Healthy Plant-Based Diet and Adverse Pregnancy Outcomes.

The Journal of nutrition·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
Same journal

Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

The Cochrane database of systematic reviews·2026
See all related articles

Progestogens do not prevent miscarriage in the general population. However, progestogen therapy significantly reduces miscarriage rates for women with a history of recurrent miscarriages, with no increased risk to mother or baby.

Area of Science:

  • Reproductive Endocrinology
  • Obstetrics and Gynecology

Background:

  • Progesterone is crucial for uterine receptivity and successful implantation.
  • Inadequate progesterone secretion is a suspected cause of miscarriage.
  • Progestogens are used to prevent spontaneous miscarriage in early pregnancy.

Purpose of the Study:

  • To evaluate the efficacy and safety of progestogen therapy for miscarriage prevention.

Main Methods:

  • Systematic review and meta-analysis of randomized and quasi-randomized controlled trials.
  • Searched multiple databases including Cochrane, MEDLINE, EMBASE, CINAHL, and NHMRC.
  • Included 15 trials with 2118 women comparing progestogens to placebo or no treatment.

Main Results:

Related Experiment Videos

  • Overall, progestogens showed no significant reduction in miscarriage risk (Peto OR 0.98; 95% CI 0.78-1.24).
  • In women with recurrent miscarriages (≥3 consecutive), progestogens significantly decreased miscarriage rates (Peto OR 0.38; 95% CI 0.20-0.70).
  • No significant differences in adverse effects for mother or baby were observed across treatment groups or administration routes.

    • Conclusions:

    • Routine progestogen use is not supported for preventing miscarriage in early to mid-pregnancy.
    • Evidence suggests progestogen benefit for women with recurrent miscarriage history.
    • Further large-scale trials are ongoing to confirm treatment efficacy for recurrent miscarriage.